Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Williams

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1205844537 CMS profile 10560445

1200 N State St Ste 420, Jackson, MS 39202

Open in the dashboard

General payments

$17,511

789 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Williams of Jackson, MS is reported in the CMS Open Payments database as having received $17,511 across 789 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,216 161
2024 General $3,861 159
2023 General $4,271 203
2022 General $3,875 188
2021 General $1,288 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Williams
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Elizabeth Williams were reported at $4,216. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Elizabeth Williams Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,288 $124 $35–$379 $132
2022 $3,875 $141 $44–$430 $149
2023 $4,271 $154 $49–$476 $160
2024 $3,861 $165 $51–$504 $164
2025 $4,216 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,854 70 payments
  2. Pfizer Inc. $1,331 81 payments
  3. Teva Pharmaceuticals USA, Inc. $1,303 70 payments
  4. SK Life Science, Inc. $1,027 43 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $848 31 payments
  6. ACADIA Pharmaceuticals Inc $844 32 payments
  7. Lundbeck LLC $837 44 payments
  8. UCB, Inc. $809 32 payments
  9. US WorldMeds, LLC $710 18 payments
  10. Lilly USA, LLC $560 36 payments
  11. Other $7,388 332 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,301 786 payments
  2. Education $210 3 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Pain $1,108 71 payments
  2. NURTEC ODT Primary Care $1,083 44 payments
  3. ZAVZPRET $874 55 payments
  4. NUPLAZID $844 32 payments
  5. QULIPTA $690 29 payments
  6. VYEPTI $553 33 payments
  7. BOTOX $499 21 payments
  8. UBRELVY $464 26 payments
  9. Briviact $459 20 payments
  10. INGREZZA $455 18 payments
  11. Other $11,416 512 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

2,197

Median for Nurse Practitioner: 389

Drug cost

$622,942

Median for Nurse Practitioner: $21,885

Branded share of claims

25.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 15 $186,549
Vimpat Lacosamide Brand 30 $62,360
Nurtec Odt Rimegepant Sulfate Brand 39 $61,234
Emgality Pen Galcanezumab-Gnlm Brand 49 $48,269
Ubrelvy Ubrogepant Brand 32 $44,807
Xcopri Cenobamate Brand 34 $38,274
Fycompa Perampanel Brand 31 $31,000
Aimovig Autoinjector Erenumab-Aooe Brand 39 $30,320
Aptiom Eslicarbazepine Acetate Brand 11 $13,346
Qulipta Atogepant Brand 12 $13,003

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$12,130

Medicare's payments for the services billed

Medicare patients

152

Average age 68

Services billed

249

97 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 57%
Diabetes 35%
Depression 34%
Ischemic heart disease 28%
Chronic kidney disease 23%
COPD 16%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $403
$403 — —
Gocovri
  • US WorldMeds, LLC $356
$356 — —
VYEPTI
  • Lundbeck LLC $191
$191 — —
NURTEC ODT
  • PFIZER INC. $189
$190 39 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $173
$173 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

789 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record